Hayashi, Masaharu
Mishima, Kazuo
Fukumizu, Michio
Takahashi, Hiroyuki
Ishikawa, Yuko
Hamada, Izumi
Sugioka, Hideyuki
Yotsuya, Osamu
Yamashita, Yushiro
Article History
Accepted: 7 June 2021
First Online: 28 June 2021
Declarations
:
: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. MH reported receiving consulting fees from Nobelpharma during the conduct of the study. KM reported receiving grants from the Japanese Ministry of Health, Labour and Welfare (H29-Seishin-Ippan-001, 19GC1012), the Japanese Ministry of Education, Science, and Technology, and the National Center of Neurology and Psychiatry Intramural Research Grant for Neurological and Psychiatric Disorders, consulting fees from Nobelpharma and Taisho Pharmaceutical, and lecture fees from Eisai, MSD, Takeda Pharmaceutical, Astellas Pharma, and Janssen Pharmaceutical. MF reported receiving grant support from Nobelpharma. YY reported receiving grant support from Nobelpharma. Nobelpharma Co., Ltd. is a company that provided the investigational drugs. HT is an employee of CMIC. YI, IH, HS, and OY are employees of Nobelpharma Co., Ltd.
: This study was performed in accordance with the Declaration of Helsinki. Ethical approval was obtained from the institutional review board at each participating institution.
: All children provided written informed ascent/consent and all their caregivers provided written informed consent before taking part.